Ms. Susan Pietropaolo reports

APTOSE ANNOUNCES DEFERRAL OF INTEREST PAYMENT

Aptose Biosciences Inc. has entered into an interest deferral agreement with Hanmi Pharmaceutical Co. Ltd., whereby Hanmi has agreed to further defer the interest payment due under the loan facility agreement dated Aug. 27, 2024, between Aptose and Hanmi for the period commencing Dec. 21, 2024, and ending on March 31, 2025, from June 27, 2025, to Dec. 31, 2025, and to defer the interest due under the 2024 loan agreement for the period commencing March 31, 2025, and ending on June 30, 2025, to Dec. 31, 2025.

About Aptose Biosciences Inc.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company's lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML), and is being developed as a front-line triplet therapy in newly diagnosed AML.

We seek Safe Harbor.